New radioactive drug for men with advanced prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new radioactive drug, Terbium-161 PSMA, for men with a type of advanced prostate cancer that has stopped responding to standard treatments. It may be an option if you have not received a similar radioactive drug before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man 18 years or older with advanced prostate cancer that has spread and is no longer responding to hormone therapy and chemotherapy (or you could not have chemotherapy).
- Your cancer is getting worse, shown by rising PSA levels, new spots on scans, or growth of tumors.
- You have not had treatment with any other radioactive drug before.
- Your latest PET scan shows the cancer cells have strong uptake of a special tracer (PSMA), meaning they bind well to the study drug.
- You are in generally good health aside from cancer, with adequate blood cell counts and kidney/liver function, and a life expectancy of at least 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental radioactive drug that targets a protein called PSMA found on prostate cancer cells. It aims to see if this drug is safe and can shrink tumors in men with advanced prostate cancer that has not responded to hormone therapy or chemotherapy.
This Phase 1/2 trial tests a PSMA-targeted radioligand treatment (a drug that delivers radiation to prostate cancer cells) in men with metastatic castration-resistant prostate cancer that has gotten worse despite standard hormone therapies. It’s designed to see how the treatment works and whether it can help shrink or control cancer, while also studying safety and dosing.
This trial tests a new drug (177Lu-PSMA-137) that targets prostate cancer cells with a special molecule to deliver radiation directly to them. It is for men with metastatic castration-resistant prostate cancer whose cancer has progressed after standard treatments like hormone therapy and chemotherapy.
This trial tests a radioactive drug called Lu 177 JH020002 for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. The drug targets a protein on cancer cells to deliver radiation directly, possibly slowing the disease.
This Phase 1 trial tests a small-molecule treatment that carries radioactive material to help treat prostate cancer that has spread and keeps growing despite standard hormone-blocking treatment. It’s mainly looking to find a safe dose and see how well the approach works in people with limited treatment options.
This early-stage trial tests a new drug called TRC003 for men with advanced prostate cancer that has spread and stopped responding to standard treatments. The drug is designed to target cancer cells that show a specific marker called PSMA.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.